The percent of samples with decreased PPP2R2A mRNA expression in lung cancer, thyroid gland cancer, breast cancer and HCC were 36.82%, 94.44%, 65.21% and 58.82% respectively. This evidence concerns the gene PPP2R2A and hepatocellular carcinoma.